TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03787953
Drug: Anti-PD-1/PD-L1 antibodies
Approvals — FDA: no, EMA: no, PMDA: no
Description: The study is a real-world study. According to the actual medical history of patients, the usage of anti-PD-1/PD-L1 antibodies was collected.
Study: NCT02989675
Drug: 10% dextrose
Normalized name: Aminosyn II 4.25% in 10% Dextrose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus of 10% dextrose 5mls/kg
Study: NCT02562430
Drug: Welbutrin XL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12.5% of participants will receive Welbutrin XL in phase 1 of the study.
Study: NCT02562430
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 87.5% of subjects will be randomized to placebo in phase 1 of the study.
Study: NCT02050360
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04893941
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02386761
Drug: Single Ascending Dose (SAD)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02386761
Drug: Multiple Ascending Dose (MAD)
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03203642
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: Tablet (identical to tesevatinib); Route of administration: orally
Study: NCT03358901
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04626297
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given SC
Study: NCT00656539
Drug: AzaSite®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ophthalmic solution; 1 drop in each eye BID for two days, then 1 drop in each eye QD for \~26 days
Study: NCT02300987
Drug: LEE011
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02300987
Drug: LEE011 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00762411
Drug: LY450139
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally once daily.
Study: NCT00762411
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally once daily.
Study: NCT00003387
Drug: chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01541215
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered subcutaneously (s.c., under the skin) once daily for 26 weeks. Subjects will discontinue placebo treatment in the open-labelled extension. Rescue treatment will be allowed if rescue criteria are met.
Study: NCT02302716
Drug: LY2963016
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT02302716
Drug: Oral Antihyperglycemic Medication
Normalized name: ANTIHYPOGLYCEMICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as per standard-of-care.
Study: NCT03561558
Drug: Ibuprofen D
Normalized name: Ibuprofen Dye Free
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen D, oral suspension, 200 mg / 5ml, manufactured by LLC Pharmtechnology, Belarus
Study: NCT03561558
Drug: Nurofen® for Children
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nurofen® for Children, Oral Suspension, 100 mg / 5 ml, marketed by Reckitt Benckiser Healthcare International Ltd, UK
Study: NCT03712202
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT03878264
Drug: CORT118335 Oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: CORT118335 900 mg spray-dried dispersion in bottle and vehicle for oral administration
Study: NCT02090933
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT01481779
Drug: LY2605541
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by SC injection with a pen device.
Study: NCT04158440
Drug: 4cycles(Placebo + platinum-based doublet chemotherapy)+13 cycles(Placebo )
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological: Placebo by IV infusion every 3 weeks (Q3W), given on cycle day 1;Drug: Cisplatin 75 mg/m\^2 by IV infusion Q3W, given on cycle day 1;Drug: Corboplatin AUC 5 by IV infusion Q3W, given on cycle day 1;Drug: Pemetrexed 500 mg/m\^2 by IV infusion Q3W, given on cycle day 1. Given only to participants with nonsquamous NSCLC.Drug:Paclitaxel 175 mg/m\^2 by IV infusion Q3W;Drug:Docetaxel 60-75 mg/m\^2 by IV infusion Q3W
Study: NCT00721916
Drug: SOL(The combination therapy of S-1, Leucovorin, and Oxaliplatin)
Normalized name: (S)-Leucovorin
DrugBank: (6R)-Folinic acid (DB03256)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-OHP 85 mg/m2 iv. for 2 hr on day 1 of each 2 weeks cycle S-1 40-60 mg bid day 1～day 7 LV 25 mg bid day 1～day 7
Study: NCT00297141
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: chemotherapy oral use
Study: NCT02899312
Drug: PSMA PET/CT scan
Approvals — FDA: no, EMA: no, PMDA: no
Description: All participants will undergo the same procedures listed in Detailed Description in the protocol section.
Study: NCT02274558
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: NBI-98854 placebo capsules
Study: NCT01113801
Drug: LY2382770
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection given monthly for 12 months
Study: NCT01113801
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection given monthly for 12 months
Study: NCT00999284
Drug: ZK200775
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of 0.3 mg/kg/h of ZK200775 over a period of 4 hours.
Study: NCT00999284
Drug: ZK200775
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of 0.75 mg/kg/h of ZK200775 over a period of 4 hours.
Study: NCT03278158
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects in the placebo arm will receive a single oral tablet containing no active drug.
Study: NCT01949051
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal aqueous 0 mcg microsuspension supplied in an amber glass bottle fitted with a white top actuated plastic metering atomising spray pump filled with a uniform white suspension
Study: NCT00973050
Drug: Casodex®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg Tabelt
Study: NCT01279915
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT01550640
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: bolus of remifentanil 1 µg/kg will be given 30 sec before induction to general anesthesia
Study: NCT00695110
Drug: Oral testosterone undecanoate (TU) (300 mg T equivalents/dose)
Normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Three capsules each containing 100 mg testosterone (T) as TU, BID. 300 mg T equivalents BID 30 minutes after initiation of breakfast and dinner meals for 7 days. A 7-14 day washout period occurred between successive Treatment Periods.
Study: NCT00695110
Drug: Oral testosterone undecanoate (TU) combined with testosterone enanthate (TE) (400 mg T equivalents/dose)
Normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Two capsules each containing 100 mg T as TU and 100 mg T as TE, BID. 400 mg T equivalents BID 30 minutes after initiation of breakfast and dinner meals for 7 days. A 7-14 day washout period occurred between successive Treatment Periods.
Study: NCT00695110
Drug: Oral testosterone undecanoate (TU) (200 mg T equivalents/dose with and without food)
Normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Two capsules each containing 100 mg T as TU, BID for 8 days. 200 mg T equivalents BID 30 minutes after initiation of meals (breakfast and dinner), except for Day 8 when the morning dose was administered fasting. A 7-14 day washout period occurred between successive Treatment Periods.
Study: NCT00695110
Drug: Oral testosterone undecanoate (TU) combined with testosterone enanthate (TE) (300 mg T equivalents/dose)
Normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Two capsules each containing 150 mg T as TU and 150 mg T as TE, BID. 300 mg T equivalents BID 30 minutes after initiation of breakfast and dinner meals for 7 days.
Study: NCT01632449
Drug: Test product
Normalized name: Patch test product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dimethyl Fumarate (BG00012)
Study: NCT01632449
Drug: Reference product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dimethyl Fumarate (BG00012)
Study: NCT01898611
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline will be used as a placebo
Study: NCT01936688
Drug: MK-3222 200 mg
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-3222 200 mg administered SC.
Study: NCT01936688
Drug: MK-3222 100 mg
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-3222 100 mg administered SC.
Study: NCT01936688
Drug: Placebo to MK-3222
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo to MK-3222 administered SC.
Study: NCT01366560
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo
Study: NCT03852355
Drug: Radiofrequency
Approvals — FDA: no, EMA: no, PMDA: no
Description: ), received bilateral 3rd occipital nerve RF under fluoroscopic guidance. Levobupivacaine (0.3 mL; 0.75%) and triamcilonone (1 mg) were injected at each level
Study: NCT03852355
Drug: Steroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: received systemic steroids oral prednisolone tablet, 10 mg/day
Study: NCT03741179
Drug: ASA-withdrawn group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients whith sFlt/PlGF ratio \< 38 at 24+0-27+6 weeks will be randomized into two arms of the trial. Patients allocated in the experimental arm will stop the ASA treatment.
Study: NCT02592785
Drug: BAY1163877
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohort 1: Single dose 600 mg on day 1, no drug on day 2 and then twice daily administration of the same dose for the remaining 19 days of cycle 1. From cycle 2 onwards all subjects are continuously treated for 21 days per cycle with twice daily administration of the same dose.~Cohort 2: Single dose 800 mg on day 1, no drug on day 2 and then twice daily administration of the same dose for the remaining 19 days of cycle 1. From cycle 2 onwards all subjects are continuously treated for 21 days per cycle with twice daily administration of the same dose.
Study: NCT02504008
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once weekly for 6 weeks
Study: NCT03645876
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000mg/m2
Study: NCT02647853
Drug: TAT4 Gel concentration A
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02647853
Drug: TAT4 Gel concentration B
Normalized name: benzocaine Oral Gel [Zilactin B]
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02647853
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02550548
Drug: Ex-9 infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ex-9 infusion will be initiated at start of hyperglycemic clamp (target: 125 mg/dL)
Study: NCT01835067
Drug: C3F8 Gas
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravitreal injection of 0.3 mls C3F8
Study: NCT00514150
Drug: normal saline 0.9%
Normalized name: BD Posiflush Normal Saline 0.9% Prefilled Syringe Solution for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV 154 mEq/L solution of NaCl 0.9% (infused at the rate of 3 ml/kg/ hour one hour before the angiographic procedure, continuing at the rate of 1 ml/kg/ hour for 6 hours after the procedure. Maximum rate of fluid permitted is that for a body weight of 110 Kg.)
Study: NCT03904836
Drug: Tobramycin
Normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 5 milligrams per kilogram intravenous for one dose
Study: NCT03486938
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral tablet
Study: NCT03486938
Drug: AGB101 220 mg tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 220 mg AGB101 active compound
Study: NCT02320149
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo-matching sarecycline tablets taken orally at the same time each day.
Study: NCT00560079
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00190996
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00539331
Drug: AZD2171
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral tablet
Study: NCT03210376
Drug: Deep Neuromuscular Blockade (NMB)
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deep Neuromuscular Blockade (NMB) given during surgery.
Study: NCT03210376
Drug: Moderate Neuromuscular Blockade (NMB)
Normalized name: Blockade
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate Neuromuscular Blockade (NMB) given during surgery.
Study: NCT02812147
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Added as described in the Arm/Group Descriptions.dded as described in the Arm/Group Descriptions.
Study: NCT02348606
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01083329
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Obese subjects will receive nicotinic acid or placebo for 16 weeks
Study: NCT01624389
Drug: F18-AV45
Normalized name: fluorodeoxyglucose F18
Approvals — FDA: no, EMA: no, PMDA: no
Description: This study will recruit a total of 200 evaluable subjects (50 cognitively normal volunteers, 100 MCI, and 50 AD, respectively) Each evaluable subject involved in this study must fulfill all the inclusion and exclusion criteria according the subject grouping.~Safety measurement will be evaluated by medical history, vital signs, physical examinations, laboratory examinations and collecting of adverse events.
Study: NCT01840501
Drug: Placebo (single dose)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo will be administered subcutaneously (an injection under the skin) as a single dose in Part 1.
Study: NCT01840501
Drug: Placebo (multiple doses)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo will be administered subcutaneously (an injection under the skin) once daily for 10 days in Part 2.
Study: NCT01285310
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Placebo tablets administered twice daily (BID) for 24 weeks during the placebo-controlled phase followed by 20mg Apremilast tablets administered BID for up to 1.5 years in active treatment / active treatment extension phase. Participants who are nonresponders will advance early to 20 mg Apremilast BID at Week 16.
Study: NCT04208620
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered subcutaneously
Study: NCT01603667
Drug: PG2
Normalized name: Fossaoprin SPG2 KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: STUDY DRUG DOSAGE:IV infusion of PG2 Injection 500 mg in 500 ml Normal Saline at a rate of 200 mg/hr with infusion started within 3-6 hrs of stroke onset and infusion of a total of 500 mg PG2 Injection in 500 ml Normal Saline or 500 ml Normal Saline will be completed within 2.5\~3.5 hrs. The same dose of PG2 Injection 500 mg will be repeated daily for the subsequent 2 days.~ROUTE OF ADMINISTRATION:Continuous IV infusion via a calibrated infusion pump DURATION FOR EACH PATIENT:90 days
Study: NCT01603667
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: STUDY DRUG DOSAGE: IV infusion of Placebo Injection 500 mg in 500 ml Normal Saline at a rate of 200 mg/hr with infusion started within 3-6 hrs of stroke onset and infusion of a total of 500 mg Placebo Injection in 500 ml Normal Saline or 500 ml Normal Saline will be completed within 2.5\~3.5 hrs. The same dose of Placebo Injection 500 mg will be repeated daily for the subsequent 2 days.~ROUTE OF ADMINISTRATION:Continuous IV infusion via a calibrated infusion pump DURATION FOR EACH PATIENT:90 days
Study: NCT01268839
Drug: TMC278
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25mg tablet once daily for 28 days
Study: NCT01268839
Drug: TMC278
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25mg tablet once daily for 14 days
Study: NCT03186365
Drug: Zepatier Oral Product
Normalized name: Zepatier Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grazoprevir, an HCV nonstructural protein 3/4A (NS3/4A) inhibitor 100 mg, plus elbasvir, an HCV NS5A inhibitor 50 mg fixed dose combination,Zepatier Oral Product, will be prescribed for 8-12 weeks
Study: NCT04260035
Drug: Sterile saline
Normalized name: Aqua Care Sterile Saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 episodic migraine patients without aura of both genders are randomized to receive a 2-hour infusion of VIP and/or sterile saline on two days, with at least one week in between.
Study: NCT00924053
Drug: EGT0001474
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohort 1: single dose of 25 mg EGT0001474 given as an oral capsule; Cohort 2: single dose of 75 mg EGT0001474 given as 3 oral capsules; Cohort 3: single dose of 150 mg EGT0001474 given as 6 oral capsules.
Study: NCT00924053
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules to match EGT0001474
Study: NCT01456260
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole placebo matching capsules, orally, once daily for 28-80 weeks.
Study: NCT01456260
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole placebo-matching capsules, orally, once daily for 28-80 weeks.
Study: NCT01456260
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-438 placebo-matching tablets, orally, once daily for 28-80 weeks.
Study: NCT00379158
Drug: Micronutrient supplements
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03976934
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: sugar pills
Study: NCT00355524
Drug: TMC114
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMC114 will be administered as oral tablets (75 milligram \[mg\] or 300 mg) twice daily at a dose ranging from 300-600 mg up to 48 weeks.
Study: NCT04740424
Drug: FS222
Normalized name: Fentanyl Sublingual Spray 222 mcg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosing of participants will occur intravenously (IV), at a fixed dose in treatment cycles once every 4 weeks (Q4W) until disease progression or unacceptable toxicity.
Study: NCT01396655
Drug: docetaxel (75 mg/m2) and doxorubicin (50 mg/m2)
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The chemotherapeutic regimen consisted of docetaxel (75 mg/m2) and doxorubicin (50 mg/m2) by intravenous infusion every 3 weeks. After three cycles of neoadjuvant chemotherapy, the patients were re-evaluated for response and underwent curative surgery. Radiologic response was evaluated using breast magnetic resonance imaging (MRI) for the primary breast tumor and chest computed tomography (CT) for axillary, supraclavicular, internal mammary lymph nodes with RECIST criteria. Both breast MRI and chest CT were performed in all the 78 patients. Subsequently, the patients received three more cycles of docetaxel and doxorubicin as an adjuvant chemotherapy, followed by hormonal or radiation therapy, if indicated.
Study: NCT01218035
Drug: zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The patients in the active-treatment group will receive a single 5 mg dose of zoledronic acid intravenously just prior to release from the hospital (about 5th day post-surgery) as an adjunct therapy. The control group will receive a placebo (saline) infusion. All infusions will be given 100 ml in volume and infused over a period of 15 minutes with a pre- and post-infusion flush with normal saline.
Study: NCT02077621
Drug: PG2
Normalized name: Fossaoprin SPG2 KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Powder for Injection, 500 mg PG2/500 ml normal saline
Study: NCT02077621
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mL normal saline
Study: NCT02345382
Drug: Atuveciclib, BAY1143572
Approvals — FDA: no, EMA: no, PMDA: no
Description: The starting dose was 20 mg BAY 1143572 once daily from Cycle 1 Day 1. Each cycle was defined as a period of 28 days. Dosing cycles continued until evidence of progression, unacceptable toxicity, consent withdrawal, or withdrawal from the study at the discretion of the investigator.
Study: NCT02119052
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00709137
Drug: spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tablet form. doses used range from 12.5-50mg po QDAY. Total duration would be until completion or study or medication intolerance.
Study: NCT00709137
Drug: amiloride
Normalized name: Amiloride
DrugBank: Amiloride (DB00594)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: amiloride 2.5-10 mg po QDAY. Duration until completion of study or until tolerance
Study: NCT02494505
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00536835
Drug: GSK461364
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK461364 will be given intravenously as a 4 hour infusion in either a final volume of 500 or 1000 mLs. The starting dose for Stage A - Schedule 1 was 50 mg and doses were to be escalated as described in protocol until maximum tolerated dose established.
Study: NCT02955693
Drug: LAS41008 120 mg / Fumaderm® 120 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of LAS41008 120 mg or Fumaderm® 120 mg in each Period
Study: NCT01898598
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive matching placebo to vismodegib for 12 weeks.
Study: NCT01875237
Drug: Mini Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5 mg/m2 by vein on Days +1, +3, +6.